olverembatinib   Click here for help

GtoPdb Ligand ID: 10630

Synonyms: compound 10a [PMID: 23301703] | GZD-824 | GZD824 | HQP-1351 | HQP1351
Approved drug PDB Ligand Immunopharmacology Ligand
olverembatinib is an approved drug (China (2021))
Compound class: Synthetic organic
Comment: Olverembatinib (HQP1351; formerly GZD824) is a novel third-generation, orally bioavailable kinase inhibitor with activity against a broad spectrum of Bcr-Abl mutants including the T315I resistance mutation [3-4]. The chemical structure for GZD824 is identical to that submitted to the WHO for the INN olverembatinib. GZD824's structure and use was first claimed in a patent from the Guangzhou Institute of Biomedicine and Health [5], but it is now being progressed by Ascentage Pharma and HealthQuest Pharma.
SARS-CoV-2: Olverembatinib has been reported to inhibit human PBM cytokine release (in vitro) as induced by the SARS-CoV-2 omicron variant [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 77.15
Molecular weight 532.22
XLogP 5.95
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1CCN(CC1)Cc1ccc(cc1C(F)(F)F)NC(=O)c1ccc(c(c1)C#Cc1cnc2c(c1)cn[nH]2)C
Isomeric SMILES CN1CCN(CC1)Cc1ccc(cc1C(F)(F)F)NC(=O)c1ccc(c(c1)C#Cc1cnc2c(c1)cn[nH]2)C
InChI InChI=1S/C29H27F3N6O/c1-19-3-5-22(14-21(19)6-4-20-13-24-17-34-36-27(24)33-16-20)28(39)35-25-8-7-23(26(15-25)29(30,31)32)18-38-11-9-37(2)10-12-38/h3,5,7-8,13-17H,9-12,18H2,1-2H3,(H,35,39)(H,33,34,36)
InChI Key TZKBVRDEOITLRB-UHFFFAOYSA-N
Bioactivity Comments
Inhibitory IC50 values for Abl1 mutants in a biochemical assay are (nM in brackets): T315I (0.68), E255K (0.27), G250E (0.71), Q252H (0.15), H396P (0.35), M351T (0.29) and Y253F (0.35) [4]. In a selectivity screening panel of 442 kinases, GZD824 was determined to bind strongly to b-RAF, DDR1, FGFR, Flt3, Kit, PDGFRα, PDGFRβ, RET, Src, Tie1, and Tie2, so its selectivity and therefore its safety with respect to off-target side-effects remains to be fully determined.
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
ABL proto-oncogene 1, non-receptor tyrosine kinase Hs Inhibitor Inhibition 9.5 pKd - 4
pKd 9.5 (Kd 3.2x10-10 M) [4]
Description: Binding affinity for nonphosphorylated Abl1 as determined using an active-site-dependent competitive binding assay (KINOMEscan).
ABL proto-oncogene 1, non-receptor tyrosine kinase Hs Inhibitor Inhibition 9.5 pIC50 - 4
pIC50 9.5 (IC50 3.4x10-10 M) [4]
Description: Inhibition of wild type Abl1 kinase activity was determined using the proprietary FRET-based Z′-Lyte assay.